|
|
|
Insider
Information: |
Goeddel David V |
Relationship: |
10% Owner |
City: |
So. San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
21,008,913 |
|
Indirect Shares
|
32,725,451 |
|
|
Direct
Value |
$107,224,205 |
|
|
Indirect Value
|
$145,808,454 |
|
|
Total
Shares |
53,734,364 |
|
|
Total
Value |
$253,032,660 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
63
|
4
|
Stock
price went up :
|
24
|
1
|
Stock
price went down : |
39
|
3
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-0.2%
|
-73.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
3,961,942 |
2014-07-29 |
0 |
Premium* |
|
Gritstone Oncology, Inc. |
GRTS |
Managing Partner |
2018-10-02 |
3,102,934 |
2018-10-02 |
0 |
Premium* |
|
Ngm Biopharmaceuticals Inc |
NGM |
Director, 10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
Rapt Therapeutics, Inc. |
RAPT |
Managing Partner, 10% ... |
2020-09-22 |
5,630,497 |
2019-11-04 |
195,401 |
Premium* |
|
Oric Pharmaceuticals, Inc. |
ORIC |
Managing Partner, 10% ... |
2020-04-28 |
4,768,181 |
|
0 |
Premium* |
|
Revolution Medicines, Inc. |
RVMD |
10% Owner |
2020-11-16 |
2,151,026 |
2020-11-16 |
3,799,202 |
Premium* |
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-05 |
1,394,333 |
2021-05-05 |
1,420,954 |
Premium* |
|
Tenaya Therapeutics, Inc. |
TNYA |
|
2021-08-03 |
0 |
2024-02-12 |
22,999,565 |
Premium* |
|
Effector Therapeutics Ord Shs |
EFTR |
10% Owner |
|
0 |
2021-08-25 |
4,309,329 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
145 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NGM |
Ngm Biopharmaceuticals In... |
Managing Partner |
|
2020-09-01 |
4 |
B |
$17.64 |
$643,754 |
D/D |
36,494 |
1,799,430 |
3.92 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Managing Partner |
|
2020-09-02 |
4 |
B |
$17.67 |
$487,604 |
D/D |
27,595 |
1,827,025 |
3.92 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-01-24 |
4 |
B |
$0.00 |
$0 |
I/I |
250,000 |
8,250 |
2.17 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-01-25 |
4 |
B |
$0.00 |
$0 |
I/I |
599,701 |
28,041 |
2.17 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-09 |
4 |
B |
$10.79 |
$897,699 |
I/I |
83,175 |
30,786 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-10 |
4 |
B |
$11.36 |
$355,283 |
I/I |
31,265 |
31,818 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-11 |
4 |
B |
$11.23 |
$935,354 |
I/I |
83,175 |
34,563 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-12 |
4 |
B |
$11.62 |
$966,678 |
I/I |
83,175 |
37,308 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-13 |
4 |
B |
$0.00 |
$0 |
I/I |
129,365 |
41,577 |
2.17 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-16 |
4 |
B |
$12.90 |
$427,891 |
I/I |
33,166 |
42,671 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-17 |
4 |
B |
$13.42 |
$1,194,779 |
I/I |
89,049 |
45,610 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-18 |
4 |
B |
$13.20 |
$827,224 |
I/I |
62,650 |
47,677 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-19 |
4 |
B |
$13.25 |
$273,922 |
I/I |
20,666 |
48,359 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-20 |
4 |
B |
$13.48 |
$256,533 |
I/I |
19,034 |
48,987 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-24 |
4 |
B |
$13.37 |
$238,325 |
I/I |
17,828 |
49,575 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-25 |
4 |
B |
$13.43 |
$581,624 |
I/I |
43,292 |
51,004 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-26 |
4 |
B |
$13.49 |
$272,582 |
I/I |
20,201 |
51,671 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-27 |
4 |
B |
$13.45 |
$36,453 |
I/I |
2,710 |
51,760 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-31 |
4 |
B |
$13.47 |
$832,267 |
I/I |
61,806 |
53,800 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-06-01 |
4 |
B |
$13.45 |
$1,237,400 |
I/I |
92,000 |
56,836 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-06-02 |
4 |
B |
$13.03 |
$445,739 |
I/I |
34,200 |
57,965 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-06-09 |
4 |
B |
$13.50 |
$13,286,174 |
I/I |
984,161 |
90,442 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-10-17 |
4 |
B |
$3.18 |
$159,140 |
D/D |
50,000 |
130,000 |
3.92 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-10-18 |
4 |
B |
$3.79 |
$303,256 |
I/I |
80,000 |
190,000 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-10-25 |
4 |
B |
$4.75 |
$242,387 |
I/I |
51,046 |
51,046 |
2.25 |
% |
|
145 Records found
|
|
Page 4 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|